Marilyn Norred has known for 30 years that she had cataracts in both eyes.
Month: December 2010
Pressure Drops Do Nothing for Post-Injection Spikes.
Archives: Pressure-lowering drops given prophylactically before intra-vitreal injections simply don’t work. The spike is transient (less than 30 in 20 minutes) and should simply be observed and managed accordingly
FDA Issues Complete Response Letter to Alimera Sciences Regarding New Drug Application for ILUVIEN
Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it received a Complete Response Letter (CRL) from the U.S. Food a…
Revised Glaucoma Guidance is Published
The Joint Group on NICE Glaucoma Guideline has published revised guidance clarifying the criteria for the referral of suspected glaucoma patients. Issued jointly by the College of Optometrists and the Royal College of Ophthalmologists, the updated ad…
Alternative Anti-VEGF Treatment Regimens in Exudative Age-related Macular Degeneration
This review explores the most current treatments for exudative age-related macular degeneration, including combination therapies. Expert Review of Ophthalmology
With Cataracts, Misinformation Seems To Abound
When medical experts talk about prevalence, they’re usually referring to how common a particular disease might be. But in the case of cataracts, they might just as well be talking about how common it is to uncover misinformation and misunderstanding ab…
PSivida Corp (PSDV) Says FDA Can’t Clear Diabetic Macular Edema Drug; Seeks Further Data On Alimera Sciences (ALIM)’ Iluvien
pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, including the investigational drug ILUVIEN® for the treatment of Diabetic Macular Edema (DME), today anno…
American Academy Of Ophthalmology Responds To Genentech Rebate Program For Lucentis Use
Genentech (Hoffman – La Roche) manufactures two critically important pharmaceuticals, Lucentis and Avastin, which are both used for treatment of several common eye diseases – including age-related macular degeneration (AMD).
Uncontrolled Hypertension, Chronic Kidney Disease May Increase Retinopathy Risk
High blood pressure and chronic kidney disease are associated with a higher incidence of retinopathy in subjects who are not diabetic, a study found.
With Cataracts, Misinformation Seems To Abound
When medical experts talk about prevalence, they’re usually referring to how common a particular disease might be. But in the case of cataracts, they might just as well be talking about how common it is to uncover misinformation and misunderstanding ab…
PSivida Corp (PSDV) Says FDA Can’t Clear Diabetic Macular Edema Drug; Seeks Further Data On Alimera Sciences (ALIM)’ Iluvien
pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, including the investigational drug ILUVIEN® for the treatment of Diabetic Macular Edema (DME), today anno…
American Academy Of Ophthalmology Responds To Genentech Rebate Program For Lucentis Use
Genentech (Hoffman – La Roche) manufactures two critically important pharmaceuticals, Lucentis and Avastin, which are both used for treatment of several common eye diseases – including age-related macular degeneration (AMD).
Uncontrolled Hypertension, Chronic Kidney Disease May Increase Retinopathy Risk
High blood pressure and chronic kidney disease are associated with a higher incidence of retinopathy in subjects who are not diabetic, a study found.
Iluvien For Diabetic Macular Edema Turned Down By FDA
Investigational drug Iluvien (fluocinolone acetonide intravitreal insert) for the treatment of diabetic macular edema cannot be approved in its present form, the FDA (Food and Drug Administration) wrote in its Complete Response Letter (CRL). Illuven is…
Santen files IND for Clinical Data’s ATL313 for primary open angle glaucoma and ocular hypertension
Clinical Data, Inc., today announced that Santen Pharmaceutical Co., Ltd., has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for Clinical Data’s highly selective adenosine A2A agonist, ATL313, for …
Enrollment begins in Phase 2 trial of RegeneRx’s RGN-259 in dry eye associated with graft vs. host disease
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company’s drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. T…
Posterior Capsule Plaque Often Observed In Pediatric Cataractous Eyes
Posterior capsule plaque occurred frequently in pediatric eyes with cataract but did not significantly affect the outcomes of IOL implantation, a study said.
Posterior Capsule Plaque Often Observed In Pediatric Cataractous Eyes
Posterior capsule plaque occurred frequently in pediatric eyes with cataract but did not significantly affect the outcomes of IOL implantation, a study said.
Laser-Assisted Cataract Surgery: Development and Application
iTunes conversion to RSS provided by Feed Flipper: [Web] – [Facebook] – [Donate!]
Dr. James Salz discusses the emerging use of lasers to assist in performing cataract surgery.
Increased Central Corneal Thickness May Skew IOP Measurements In Diabetic Eyes
Central corneal thickness was higher in diabetic patients than in nondiabetic patients, suggesting the potential for inflated IOP measurements in diabetic eyes, a study found.